ライフサイエンスコーパス: alkylating

1 ere treated with RT, and almost 40% received alkylating agent (AA) -containing chemotherapy (predomin

2 Cumulative exposure to alkylating agent (AA) was notably lower in the G studies

3 erapy with bortezomib, dexamethasone, and an alkylating agent (BDex+AA) is associated with improved b

4 t donor blood cells, modified in vitro by an alkylating agent (modified immune cells [MICs]), induced

5 rgeting of KRAS mutant DNA using a synthetic alkylating agent (pyrrole-imidazole polyamide indole-sec

6 from the corresponding N-alkyl imidazole, an alkylating agent (usually MeI), and sodium borohydride (

7 yes/no), radiation to the neck (yes/no), and alkylating agent (yes/no).

8 abine), 4-6 of 6 matched dUCB-other (n = 40; alkylating agent + fludarabine +/- TBI), and 8 of 8 (n =

9 Compared with temozolomide, a clinical DNA-alkylating agent against glioma, 6OTD required lower con

10 at G4 targeting of this clinically important alkylating agent alters the overall mechanism of action.

11 Conditioning regimens consisted of an alkylating agent and fludarabine, and GVHD prophylaxis i

12 alidomide, pomalidomide, daratumumab, and an alkylating agent and had disease refractory to at least

13 rate that ALX, through its dual action as an alkylating agent and topoisomerase inhibitor, represents

14 Treatment of animals with the alkylating agent azoxymethane resulted in both liver tox

15 TH-302, a prodrug of the cytotoxic alkylating agent bromo-isophosphoramide mustard, is pref

16 more than 50% decrease in the LD(50) for DNA-alkylating agent carmustine (BCNU), which is commonly us

17 10.5-41.6] since diagnosis) who had received alkylating agent chemotherapy but no radiation therapy.

18 Increasing doses of uterine radiation and alkylating agent chemotherapy were strongly associated w

19 ing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities

20 Given the activity of the lenalidomide-alkylating agent combination in myeloma, we designed thi

21 ients with prior exposure to fludarabine and alkylating agent combinations, and patients with prior e

22 increase in mutations and sensitivity to an alkylating agent compared with the WT hMPG.

23 subsequent sarcoma among those who received alkylating agent doses in the third tertile (RR, 14.9; 9

24 Direct normoxic PARP1 activation by a DNA alkylating agent enhanced Bnip3 expression, and caused B

25 ta define the dose-specific relation between alkylating agent exposure and semen variables in adult s

26 Alkylating agent exposure was associated with an 8.8-fol

27 Alkylating agent exposure was estimated using the cyclop

28 rolidinone (NMP) established that the active alkylating agent is the azetidinium ion, 4, 4-azoniaspir

29 under basic conditions in the presence of an alkylating agent leads to atropselective O-alkylation wi

30 ild-type and Aag(-/-) cells treated with the alkylating agent methyl methanesulfonate (MMS).

31 ar protein reorganization on exposure to the alkylating agent methyl methanesulfonate (MMS).

32 leotide resolution in yeast treated with the alkylating agent methyl methanesulfonate (MMS).

33 e was enhanced upon DNA damage caused by the alkylating agent methyl methanesulfonate and that the re

34 arly severe in mutant cells treated with the alkylating agent methyl methanesulfonate.

35 Administration of the DNA-alkylating agent methylazoxymethanol acetate (MAM) on em

36 s-link in vitro and in HeLa cells exposed to alkylating agent methylmethanesulfonate (MMS).

37 312 helps to prevent tumour induction by the alkylating agent MNU, which predominantly caused T cell

38 The trichloroacetimidate alkylating agent must be a stable cation precursor for t

39 man lymphoblastoid cell lines exposed to the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (M

40 o had not had a response to rituximab and an alkylating agent or had had a relapse within 6 months af

41 All patients received alkylating agent plus fludarabine; 792 received allograf

42 lowed by radiotherapy and treatment with the alkylating agent Temozolomide (TMZ), can extend patient

43 RvIII influences the sensitivity towards the alkylating agent temozolomide (TMZ).

44 tant radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

45 udes radiation and chemotherapy with the DNA alkylating agent temozolomide (TMZ).

46 nergistic cytotoxicity of treatment with the alkylating agent temozolomide in combination with the PA

47 y the proteasome inhibitor bortezomib or the alkylating agent temozolomide.

48 increased invasiveness and resistance to the alkylating agent temozolomide.

49 s glioblastoma-resistant cancer cells to the alkylating agent temozolomide.

50 y radiotherapy and chemotherapy with the DNA alkylating agent temozolomide.

51 ; tetrachlorobenzoquinone (TCBQ) is a potent alkylating agent that reacts with cellular thiols at a d

52 es with increased therapeutic sensitivity to alkylating agent therapy.

53 of the cobalt complex with 0.75 mol % of the alkylating agent to afford the desired products in up to

54 A and R69F mutants are more sensitive toward alkylating agent toxicity, revealing the key role of Arg

55 lthough the gene transcription is induced by alkylating agent treatment, the protein is degraded in v

56 Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma

57 Temozolomide is a DNA-alkylating agent used to treat brain tumors, but resista

58 A adducts based on the reactivity of the DNA alkylating agent was demonstrated by inclusion of an ion

59 An isoxazole-based alkylating agent was developed to selectively alkylate c

60 TMZ is an alkylating agent which is water soluble.

61 le mice with melphalan (MLP), a bifunctional alkylating agent widely used in chemotherapy, induces DN

62 g with two alkylating agents (p=0.015 vs one alkylating agent) and last available pre-HSCT bilirubin

63 ly accelerated by treatment of mice with the alkylating agent, N-ethyl-N-nitrosourea (ENU), regardles

64 Moreover, the current generated by the alkylating agent, N-ethylmaleimide, occluded the effect

65 d after reduction of receptor reserve by the alkylating agent, phenoxybenzamine, as it reduced the ma

66 ent of polymers with methyl iodide (MeI), an alkylating agent, to convert polymer-bound tertiary amin

67 confirm the formation of PARP-1 DPCs during alkylating agent-induced base excision repair (BER) and

68 icrotubule toxin and a duocarmycin-class DNA-alkylating agent.

69 s as a topoisomerase inhibitor as well as an alkylating agent.

70 ore as well as on the aromatic moiety of the alkylating agent.

71 ng bromocrotonate as the activated methylene alkylating agent.

72 ine is a newly approved and better-tolerated alkylating agent.

73 N-ethylmaleimide (NEM), a cysteine-selective alkylating agent.

74 lex was more resistant to inactivation by an alkylating agent.

75 ing regimen, with 73 also receiving a second alkylating agent.

76 yl trifluoromethanesulfonate as a reversible alkylating agent.

77 verse nucleophiles using methylarenes as the alkylating agent.

78 The use of an alkene as the formal "alkylating" agent associated with the tolerance for nume

79 al tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT.

80 %) or in association with rituximab (21.1%), alkylating agents (36.8%) or a combination of cyclophosp

81 ies), including proteasome inhibitors (91%), alkylating agents (91%), autologous stem cell transplant

82 , we quantified cumulative doses of specific alkylating agents (AAs) and reconstructed radiation dose

83 not significantly elevated after exposure to alkylating agents (hazard ratio, 1.27; 95% CI, 0.3 to 3.

84 multivariate analysis, conditioning with two alkylating agents (p=0.015 vs one alkylating agent) and

85 Treatment with alkylating agents also was not significantly associated

86 s been increasingly used in combination with alkylating agents and dexamethasone.

87 duced by lysosomal injury resulting from DNA alkylating agents and hypotonic shock, whereas it promot

88 ive SCID suggest that minimizing exposure to alkylating agents and ionizing radiation is important fo

89 ne (1-MeA) is formed in DNA by reaction with alkylating agents and naturally occurring methyl halides

90 survival following first-line treatment with alkylating agents and purine analogs.

91 ated with defective apoptosis in response to alkylating agents and purine analogues.

92 plausible cause-effect relationship between alkylating agents and PVOD.

93 ne questionnaire, and quantified exposure to alkylating agents and radiation therapy.

94 We quantified chemotherapy with alkylating agents and radiotherapy doses to the testes a

95 ses and related quaternary ammonium salts as alkylating agents and singlet oxygen sensitizers.

96 5), and a dose response was observed between alkylating agents and SMN rate (RR, 1.2/5,000 mg/m(2); 9

97 Linear dose responses were seen between alkylating agents and SMN rates and between anthracyclin

98 specifically increases in response to S(N)2 alkylating agents and to a lower extent to S(N)1 alkylat

99 compromise fertility, especially exposure to alkylating agents and whole body irradiation, which caus

100 ng adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential expos

101 DNA-alkylating agents are commonly used to kill cancer cells

102 s in Diels-Alder reactions and electrophilic alkylating agents are described.

103 nt, testicular radiotherapy at any dose, and alkylating agents at cyclophosphamide equivalent doses o

104 N) or CB-839, hypersensitize cancer cells to alkylating agents both in vitro and in vivo.

105 poxic microenvironment induces resistance to alkylating agents by activating targets in the mammalian

106 te here that halogenated benzothiazine-based alkylating agents can be utilized to rapidly measure the

107 Alkylating agents can induce sustained drug-free remissi

108 ored by depletion of Top1, illustrating that alkylating agents can trigger cytotoxic Top1-breaks.

109 one alone (control group) concomitantly with alkylating agents containing chemotherapy.

110 rates for the activity of the major types of alkylating agents defined by their nucleophilic substitu

111 tissue extracts, and the efficiencies of the alkylating agents enable completion of all three labelin

112 Trichloroacetimidates are useful alkylating agents for aromatic amines, requiring only a

113 nd their relationship to genotype and use of alkylating agents for conditioning.

114 thiol derivatives with Michael acceptors and alkylating agents furnished thioglycosides and (1,1)-thi

115 pated and unknown DNA adducts induced by DNA alkylating agents in biological samples.

116 Crick faces of nucleobases are accessible to alkylating agents in canonical dsDNA and that Hoogsteen

117 icancer cotherapies, used as enhancements of alkylating agents in chemotherapy.

118 erase (MGMT), a key enzyme for resistance to alkylating agents in glioblastoma patients.

119 Due to the abundant presence of alkylating agents in living cells and the environment, D

120 ), radiation dose-volume, anthracyclines and alkylating agents in non-chest irradiated survivors, and

121 ht alcohols such as ethanol could be used as alkylating agents in this methodology.

122 was observed among survivors not exposed to alkylating agents included in the CED (P > 0.29).

123 Alkylating agents induce cytotoxic DNA base adducts.

124 reviously shown in tumor xenografts that DNA alkylating agents induce sporadic cell necrosis and regr

125 tidases and rapidly and selectively releases alkylating agents into tumor cells.

126 oselectivity of ambident nucleophiles toward alkylating agents is a fundamental problem in heterocycl

127 However, use of preconditioning with alkylating agents is associated with a greater likelihoo

128 Exposure to high doses of alkylating agents is associated with increased risk of i

129 The benefit of cancer chemotherapy based on alkylating agents is limited because of the action of DN

130 terocycles using allyl or benzyl alcohols as alkylating agents is presented.

131 DNA alkylating agents like nitrogen mustard (NM) are easily

132 ssays and potentiate the cytotoxicity of the alkylating agents methylmethane sulfonate and temozolomi

133 F can be developed to enhance the effects of alkylating agents on cancer cells.

134 cing intracellular NAD(+) depletion, such as alkylating agents or direct NAD(+) synthesis inhibitors,

135 itivity was not observed upon treatment with alkylating agents or UV irradiation.

136 cacy compared with corticosteroids alone and alkylating agents plus corticosteroids to achieve comple

137 Although cytotoxic alkylating agents possessing two electrophilic reactive

138 Treatment with alkylating agents resulted in a hypermutator phenotype a

139 with 100% sperm retrieval while exposure to alkylating agents resulted in a significantly lower sper

140 Monofunctional alkylating agents sensitize MGMT-deficient tumor cells t

141 Other alkylating agents such as cyclic alkanes, ethers, and al

142 ssion confers significant sensitivity to DNA alkylating agents such as temozolomide, providing a natu

143 n the presence of sodium dodecyl sulfate and alkylating agents that irreversibly inhibit Ubl protease

144 Both classes of compound are potent alkylating agents that may need to be considered in futu

145 red with different alcohols, and shown to be alkylating agents to a range of nucleophiles.

146 Here we show that the addition of common alkylating agents to growing cultures of Escherichia col

147 Oxazaphosphorines are alkylating agents used in routine clinical practices for

148 n whose mothers were exposed to radiation or alkylating agents versus neither, the prevalence of anom

149 eloped a strategy to harness alkyl amines as alkylating agents via C-N bond activation.

150 on, corticosteroids, and chronic exposure to alkylating agents via distinct molecular routes involvin

151 Pre-BMT exposure to alkylating agents was associated with an increased risk

152 Exposure to alkylating agents was observed in 83.8% of cases, mostly

153 ge, testicular radiotherapy, and exposure to alkylating agents were associated with LCF, which was as

154 4-(p-nitrobenzyl)pyridine (NBP), a trap for alkylating agents with nucleophilic characteristics simi

155 s to be employed as nonhazardous and greener alkylating agents with the formation of environmentally

156 re susceptible to bi- and tri-functional DNA alkylating agents with this phenotype readily complement

157 no optimal approach that uses standard dose-alkylating agents without significant late effects.

158 st the hypothesis that increased exposure to alkylating agents would be associated with decreased spe

159 s, a mild protocol using simple and abundant alkylating agents would have considerable use in the syn

160 an catalyze the hydrolysis of the potent DNA-alkylating agents yatakemycin (YTM) and CC-1065.

161 EN), to alkyl diazohydroxides (which are DNA-alkylating agents) and also aldehydes (HCHO from DMN and

162 s-resistant drugs used for conditioning (eg, alkylating agents) could favor elimination of residual c

163 tients, is associated with prior exposure to alkylating agents, and a high frequency of TP53 loss or

164 nerated by chain-terminating nucleosides and alkylating agents, and base oxidation both in the nuclea

165 r-stable and inexpensive nitroalkanes as the alkylating agents, and delivers synthetically versatile

166 op1 inhibitors, but also to Top2 inhibitors, alkylating agents, and DNA synthesis inhibitors.

167 trobenzofurazan-based scaffolds, maleimides, alkylating agents, and electrophilic aldehydes, toward c

168 s of mutations in yeast strains treated with alkylating agents, as well as in whole-exome and whole-g

169 repair kinetics and increases sensitivity to alkylating agents, but not other forms of DNA damage.

170 arious histologic subtypes more sensitive to alkylating agents, but they have no effect in wild-type

171 rimary tumor, therapeutic radiation, but not alkylating agents, confer an increased risk of SNs.

172 arly higher cumulative doses of platinum and alkylating agents, face increased SMN risk.

173 ed necrotic cell death, induced by cytotoxic alkylating agents, hyperactivation of poly-ADP-ribose po

174 sm may not augment some regionally delivered alkylating agents, leading to a net increase in tumor si

175 Using thiol-alkylating agents, mass spectrometry, and an assay for a

176 a (WM) and closely related disorders include alkylating agents, purine analogs, and monoclonal antibo

177 agents in WM include monoclonal antibodies, alkylating agents, purine analogs, proteasome inhibitors

178 Treatment with alkylating agents, second-line therapy, and age older th

179 a young age, as well as pre-BMT exposure to alkylating agents, should inform breast cancer screening

180 Alkylating agents, such as cyclophosphamide, set up the

181 changes color upon the exposure to dangerous alkylating agents, such as iodomethane vapor, without th

182 proaches with alkyl halides or sulfonates as alkylating agents, the use of unactivated olefins for al

183 n histone deacetylase inhibitors (HDACi) and alkylating agents, we present the discovery of a series

184 oma cells to apoptosis following exposure to alkylating agents, while not affecting primary melanocyt

185 foci specifically upon exposure of cells to alkylating agents.

186 nse of malignant melanoma cells treated with alkylating agents.

187 ator compound for many types of carcinogenic alkylating agents.

188 and can detect both gas- and solution-phase alkylating agents.

189 t severe, pulmonary vascular complication of alkylating agents.

190 s makes them significantly more sensitive to alkylating agents.

191 nd intrastrand cross-linking agents, but not alkylating agents.

192 h antimetabolites, T-cell inhibitors, and/or alkylating agents.

193 ylation strategy using simple olefins as the alkylating agents.

194 ersus-host disease regardless of exposure to alkylating agents.

195 n spectra and signatures associated with DNA alkylating agents.

196 poor growth in ARTEMIS deficiency and use of alkylating agents.

197 m to repair DNA adducts and are sensitive to alkylating agents.

198 e metabolism to form potent DNA minor groove-alkylating agents.

199 otizing scleritis may respond to IMT, mainly alkylating agents.

200 2-diketones using simple terminal olefins as alkylating agents.

201 ses, these compounds convert into active DNA-alkylating agents.

202 ge may protect the active site cysteine from alkylating agents.

203 es, which include ionizing radiation and DNA-alkylating agents.

204 unity and tumor clearance in response to DNA alkylating agents.

205 tion with dexamethasone, anthracyclines, and alkylating agents.

206 capacity to repair DNA damage induced by DNA alkylating agents.

207 primary aliphatic alcohols to be employed as alkylating agents.

208 aggregates in the presence of oxidizing and alkylating agents.

209 reactive methyl donor, and by reaction with alkylating agents.

210 adaptive response to exogenous nucleic acid-alkylating agents.

211 SCC foci formation and are hypersensitive to alkylating agents.

212 ed upon exposure to endogenous and exogenous alkylating agents.

213 ation of ketones using simple alkenes as the alkylating agents.

214 protects cells from carcinogenic effects of alkylating agents; however, MGMT is silenced by promoter

215 linked with increased susceptibility to DNA alkylating and inter-strand cross-linking agents.

216 lating agents and to a lower extent to S(N)1 alkylating and oxidative agents.

217 on but show reduced viability in the face of alkylating and oxidative damage, increased mtDNA degrada

218 sses necrotic cell death induced by numerous alkylating and oxidizing agents while having no effect o

219 We extracted doses of 14 alkylating and similar DNA interstrand crosslinking drug

220 Maleimide-based, alkylating, and aldehydic thiol labeling reagents provid

221 reported correlation between sensitivity to alkylating anticancer agents and topoisomerase inhibitor

222 be superior in the colorimetric assay of the alkylating anticancer drug cyclophosphamide.

223 e affords ethanesultone (ES), which displays alkylating capacity on the nucleophile 4-(p-nitrobenzyl)

224 oward the mutagenic activity of the SN2-type alkylating carcinogens in cigarettes.

225 us agents such as reactive oxygen species or alkylating chemicals have the potential to profoundly af

226 DNA damage caused by alkylating chemicals induces an adaptive response in Esc

227 ratinocytes upon exposure to UVB and the DNA-alkylating chemicals such as methyl methanesulphonate (M

228 and tumors from patients exposed to SN2-type alkylating chemicals.

229 '-nitro-nitrosoguanidine (MNNG, a common DNA-alkylating chemotherapeutic agent).

230 that clinically relevant dosages of standard alkylating chemotherapies, such as temozolomide and cycl

231 ey show that in ARTEMIS patients, the use of alkylating chemotherapy agents is associated with a high

232 Dose-response relationships for alkylating chemotherapy and age at treatment are both li

233 otherapy and dose-response relationships for alkylating chemotherapy and age at treatment.

234 Dose relationship between alkylating chemotherapy and POF occurrence was linear.

235 In women treated without alkylating chemotherapy at age younger than 32 years and

236 Resistance toward alkylating chemotherapy but not radiotherapy was depende

237 ssue was not more predictive for response to alkylating chemotherapy in patients who received concomi

238 Alkylating chemotherapy is a central component of the ma

239 Alkylating chemotherapy or pelvic radiotherapy diminishe

240 Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and

241 erapy for malignancies that are treated with alkylating chemotherapy, and the contribution of standar

242 1) as a key determinant of resistance toward alkylating chemotherapy, driven by hypoxia but also by t

243 als are often conducted after treatment with alkylating chemotherapy, given either as standard therap

244 Despite therapy with surgery, radiation, and alkylating chemotherapy, most people have recurrence wit

245 s induced and predictive of poor response to alkylating chemotherapy.

246 d to avoid exposing responder lymphocytes to alkylating chemotherapy.

247 t macaques that were rendered infertile with alkylating chemotherapy.

248 Alkylating commercial 2-pyridinesulfonylacetonitrile wit

249 Nitrogen mustards (NMs) are DNA-alkylating compounds that represent the earliest antican

250 xins, including UV-B and ionizing radiation, alkylating compounds, aristolochic acid, aflatoxin B1, a

251 ntage of increased residence time at EGFR by alkylating Cys797 and thereby preventing toxic effects.

252 To model endogenous alkylating damage, we determined the mutation spectrum c

253 milar episulfonium ion intermediate, thereby alkylating DNA and leading to eventual cell death.

254 Mechanistically, upon oxidative stress or alkylating DNA damage, PARP1 interacts with and attaches

255 rast, inhibition of PARP by PARPi attenuates alkylating DNA damage-induced EZH2 downregulation, there

256 an episulfonium ion intermediate capable of alkylating DNA.

257 18 times more sensitive to Bizelesin, a DNA alkylating drug compared to WT parasites as reflected by

258 oietic stem-cell transplantation, cumulative alkylating drug dose, and an interaction between age at

259 to these updated consensus recommendations, alkylating drugs (bendamustine, cyclophosphamide) and pr

260 Greater doses of contemporary alkylating drugs and cisplatin were associated with a de

261 g Rnf4 are hypersensitive to hyroxyurea, DNA alkylating drugs and DNA crosslinking agents, but this s

262 ression and restores chemosensitivity of DNA-alkylating drugs in mouse models.

263 ease in children and parental treatment with alkylating drugs or preconception radiation doses to the

264 melanoma therapy with temozolomide and other alkylating drugs suggests a combination approach where c

265 contribute to resistance of melanomas to the alkylating drugs temozolomide, dacarbazine, and fotemust

266 gammaglobulinemia, conventional therapy with alkylating drugs, and recently, purine analogs and mAb-a

267 d with the sensitivity toward venetoclax and alkylating drugs.

268 Thus, these specialized alkylating enzymes have dramatic and fully opposed effec

269 at alternatives, such as cyclophosphamide or alkylating-free combinations, should be considered inste

270 yl bond of TrapG generates a highly reactive alkylating group that facilitates the attachment of the

271 tives characterized by variously substituted alkylating groups on the nitrogen atom of the quinolinon

272 nts, we present the discovery of a series of alkylating HDACi using a pharmacophore-linking strategy.

273 ameliorating the efficacy of the most common alkylating immunomodulatory compound.

274 lar modeling studies with both mono- and bis-alkylating ligands indicated that the ligands fit tightl

275 DNA crosslinking agent based on a novel DNA-alkylating moiety.

276 adducts in DNA that are generated by various alkylating mutagens and drugs.

277 lls treated with PR104A, an experimental DNA alkylating nitrogen mustard prodrug currently under inve

278 tes to resistance of tumors treated with DNA-alkylating or -oxidizing agents, and has recently been i

279 s serve the dual role of oxidants as well as alkylating or arylating agents.

280 nonepimerizing chemo- and enantioselective N-alkylating procedure has been developed via oxidation/im

281 Addition of two equivalents of an alkylating reagent to UO2 X2 (L)2 (X=Cl, Br, I, OTf; L=t

282 The alkylating reagent, N-(phenylseleno)phthalimide (NPSP),

283 s polymerization (ROMP) for use as efficient alkylating reagents is reported.

284 rs using alcohols for in situ preparation of alkylating reagents is reported.

285 suggests a kinetic anionic activation of the alkylating reagents occurs, favoring nucleophilic additi

286 ha-1 degrees and alpha-2 degrees amines into alkylating reagents via Katritzky pyridinium salts.

287 icable use of unactivated alcohols as latent alkylating reagents, achieved via the successful merger

288 ntal lineCH(t)Bu(OTf)] and the corresponding alkylating reagents, LiCH2CHR (R = H, CH3(unstable), CH2

289 ass, such as lignocellulose, are employed as alkylating reagents.

290 strategy for replacing toxic, electrophilic alkylating reagents.

291 tion of heteroarenes, using alcohols as mild alkylating reagents.

292 y available uranyl salts, silyl halides, and alkylating reagents.

293 pecific quantitative approach integrating an alkylating resin-assisted capture and mass spectrometry-

294 alogues might be exploited to activate a DNA-alkylating species selectively in hypoxic tissue.

295 the pathogen Brucella abortus does encounter alkylating stress during the first hours of macrophage i

296 ar pathogenic bacteria have to cope with DNA alkylating stress within host cells.

297 dification is removed through catalysis; and alkylating the cysteine blocks activity.

298 In this study, we show that whereas DNA alkylating therapy leads to a complete tumor regression

299 kine array analysis reveals that whereas DNA alkylating treatment leads to suppression of protumor cy

300 The alkylating warhead of the pancreatic cancer drug strepto